Figure 5.

YYFZBJS inhibited ETBF-induced colorectal tumor development in AOM/DSS model. A. Macroscopic view of the representative mouse large intestinal shows several polypoid and discoid colonic tumors from different groups of ETBF-infected mice administered with or without YYFZBJS as shown in Figure S1. GF/AOM/DSS mice were infected with ETBF. During ETBF infection, the YYFZBJS-treated group was orally gavaged with YYFZBJS (15.3 g/kg, p.o., once a day). B. Tumors number and colon length distribution. C, D. Immunohistochemical staining with an antibody against STAT3, CD163, and Arg-1 among Vehicle group, ETBF group and ETBF+YYFZBJS group. Magnification bars, 100 μM. Data are presented as the means ± SD of 8 animals per experimental group with Welch’s correction two-tailed t-test. *P<0.05, **P<0.01, vs. Vehicle; #P<0.05, ##P<0.01, vs. ETBF group. E. Representative gating strategy used to identify pulmonary macrophage subsets from intestinal tumor tissue in the GF/AOM/DSS mouse model is shown. Macrophages were analyzed using flow cytometry analysis of the M2 macrophage marker CD206 in the F4/80⁺ cell fraction. The data are presented as the mean ± SD of at least three independent experiments. F. IL-6, IL-12, TGF-β, and TNF-α levels in Tumor were evaluated using ELISA. The data are presented as the mean ± SD of at least three experiments. *P<0.05, **P<0.01, Vehicle vs. ETBF; #P<0.05, ##P<0.01, Vehicle vs. ETBF+YYFZBJS.